Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery

Author(s): Harmeet Kaur, Sapna D. Desai, Virender Kumar, Pooja Rathi, Jasbir Singh

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 16 , Issue 11 , 2016

Become EABM
Become Reviewer

Graphical Abstract:


New polymer therapeutics like polymer-drug conjugates (PDCs) are developing day by day. Heterocyclic drugs with excellent cytotoxic properties are available, but lack of their specificity makes them available to the normal cells also, which is the main cause of their toxicity. Drugs in the form of PDCs make delivery possible to the specific sites. Most of the PDCs are designed with the aim to either target and/or to get activated in specific cancer microenvironments. Therefore, the most exploited targets for cancer drug delivery are; cancer cell enzymes, heat shock protein 90 (HSP90), multi-drug resistance (MDR) proteins, angiogenesis, apoptosis and cell membrane receptors (e.g., folates, transferrin, etc.). In this review, we will summarize PDCs of heterocyclic drugs, like doxorubicin (DOX), daunorubicin, paclitaxel (PTX), docetaxel (DTX), cisplatin, camptothecin (CPT), geldanamycin (GDM), etc., and some of their analogs for efficient delivery of drugs to cancer cells.

Keywords: Cancer, targeting, endocytosis, angiogenesis, apoptosis, ligand, dendrimer, micelles, block copolymers.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [1355 - 1377]
Pages: 23
DOI: 10.2174/1871520615666160504094044
Price: $65

Article Metrics

PDF: 54
PRC: 1